Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis

Thorax 65 巻 4 号 334-340 頁 2010 発行
アクセス数 : 997
ダウンロード数 : 247

今月のアクセス数 : 3
今月のダウンロード数 : 3
ファイル情報(添付)
Thorax_65_334.pdf 1.08 MB 種類 : 全文
タイトル ( eng )
Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis
作成者
Hattori Noboru
Tanimoto Takuya
Furonaka Makoto
Ishikawa Nobuhisa
Yokoyama Akihito
収録物名
Thorax
65
4
開始ページ 334
終了ページ 340
抄録
Background and aim: There is a growing body of evidence demonstrating that plasminogen activator inhibitor-1 (PAI-1) is involved in the progression of pulmonary fibrosis. In fact, PAI-1 knockout mice are protected from bleomycin-induced pulmonary fibrosis. This study was conducted to determine whether the intrapulmonary administration of small interfering RNA (siRNA) targeting PAI-1 (PAI-1-siRNA) limits the development of bleomycin-induced pulmonary fibrosis.

Methods: Lung biopsies from patients with idiopathic pulmonary fibrosis (IPF) were stained for PAI-1. The distribution of siRNA in the lung, the PAI-1 level in bronchoalveolar (BAL) fluid and the extent of fibrotic changes in the lung were evaluated following the intranasal administration of PAI-1-siRNA in a mouse model of bleomycin-induced pulmonary fibrosis. The effect of PAI-1-siRNA on the epithelial to mesenchymal transition (EMT) was also evaluated using a mouse lung epithelial cell line, LA-4.

Results: PAI-1 was overexpressed in the hyperplastic type 2 pneumocytes lining the honeycomb lesions of patients with IPF. The single intranasal instillation of PAI-1-siRNA resulted in the diffuse uptake of siRNA into the epithelial cells lining the dense fibrotic lesions. The repeated administration of PAI-1-siRNA initiated during either the inflammatory or the fibrotic phase into bleomycin-injured mice reduced the PAI-1 level in BAL fluid and limited the accumulation of collagen in the lungs. EMT induced by transforming growth factor β (TGFβ) in LA-4 cells was inhibited by transfection with PAI-1-siRNA.

Conclusions: The direct suppression of PAI-1 in the lung by the intrapulmonary administration of PAI-1-siRNA attenuated the development and progression of pulmonary fibrosis. The inhibition of EMT may be, at least in part, involved in this effect.
NDC分類
医学 [ 490 ]
言語
英語
資源タイプ 学術雑誌論文
出版者
BMJ Publishing Group
発行日 2010
権利情報
Copyright (c) 2010 BMJ Publishing Group & British Thoracic Society
出版タイプ Version of Record(出版社版。早期公開を含む)
アクセス権 オープンアクセス
収録物識別子
[ISSN] 0040-6376
[DOI] 10.1136/thx.2009.119974
[NCID] AA00863090
[DOI] http://dx.doi.org/10.1136/thx.2009.119974